[{"id":"34e5be18-1470-4c80-b04a-c3f608ab3951","acronym":"","url":"https://clinicaltrials.gov/study/NCT00637247","created_at":"2022-04-16T16:04:53.025Z","updated_at":"2024-07-02T16:37:01.477Z","phase":"Phase 2","brief_title":"A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer","source_id_and_acronym":"NCT00637247","lead_sponsor":"AmpliMed Corporation","biomarkers":" G6PD","pipe":"","alterations":" ","tags":["G6PD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Amplimexon (imexon)"],"overall_status":"Completed","enrollment":" Enrollment 142","initiation":"Initiation: 04/01/2008","start_date":" 04/01/2008","primary_txt":" Primary completion: 05/01/2010","primary_completion_date":" 05/01/2010","study_txt":" Completion: 06/01/2010","study_completion_date":" 06/01/2010","last_update_posted":"2019-03-20"}]